| Literature DB >> 29074964 |
Jie Yang1,2, Xia Wang3, Jian Ping Yu4, Jing Hang5, Pablo Lavados6, Thompson Robinson7, Hisatomi Arima8, Richard I Lindley3, Craig S Anderson9, John Chalmers3.
Abstract
Door-to-needle time (DNT) is a key performance indicator for efficient use of intravenous thrombolysis in acute ischemic stroke (AIS). We aimed to determine whether DNT improved over time in the Enhanced Control of Hypertension and Acute Stroke Study (ENCHANTED) and the clinical predictors of DNT. Temporal trends in DNT were assessed across fourths of time since activation of study centers using generalized linear model. Predictors of long DNT (>60 min) were determined in logistic regression models. Overall mean DNT (min) was 71.8 (95% confidence interval [CI] 70.4-73.2), but decreased significantly over time (fourths): 77.9 (74.9-80.9), 69.3 (66.7-72.0), 69.1 (66.5-71.8) and 71.4 (68.7-74.2) (P for trend, 0.003). The reduction in DNT was particularly marked in China (P for trend, 0.001), but was not significant across the other participating countries (P for trend, 0.065). Independent predictors of long DNT were recruitment from China, short onset-to-door time, lower numbers of patients treated per center, higher diastolic blood pressure, off-hour admission, and absence of proximal clot occlusion. DNT in ENCHANTED declined progressively during the trial, especially in China. However, DNT in China is still longer than the key performance parameter of ≤60 minutes recommended in guidelines. Effective national programs are needed to improve DNT in China.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29074964 PMCID: PMC5658430 DOI: 10.1038/s41598-017-14164-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics of patients with acute ischemic stroke, according to door-to-needle time above and below 60 minutes for use of intravenous thrombolysis treatment.
| DNT ≤60 min | DNT >60 min |
| OR (95%CI) | aOR (95%CI) |
| |
|---|---|---|---|---|---|---|
| N = 1316 | N = 1903 | |||||
| Age, years | 68 (13) | 66 (13) | <0.0001 | 0.89 (0.85–0.95)* | ||
| Female | 479 (36) | 742 (39) | 0.136 | |||
| Region of recruitment | <0.0001 | |||||
| China | 235 (18) | 1147 (60) | 6.98 (5.90–8.26) | 9.75 (7.70–12.35) | <0.0001 | |
| Others | 1081 (82) | 756 (40) | 1.0 | |||
| Clinical features | ||||||
| Systolic BP, mmHg | 149 (20) | 150 (19) | 0.059 | |||
| Diastolic BP, mmHg | 83 (13) | 86 (13) | <0.0001 | 1.18 (1.12–1.25)* | 1.07 (1.00–1.14)* | 0.037 |
| Heart rate, beats per minute | 80 (16) | 79 (15) | 0.156 | |||
| NIHSS score | 8 (5–13) | 8 (5–14) | 0.523 | |||
| ≥14 | 315 (24) | 516 (27) | 0.043 | 1.18 (1.01–1.39) | ||
| GCS score | 15 (14–15) | 15 (13–15) | 0.0003 | |||
| Severe (3–8) | 33 (3) | 99 (5) | 0.0002 | 2.13 (1.43–3.18) | ||
| Medical history | ||||||
| Hypertension | 822 (63) | 1194 (63) | 0.871 | |||
| Previous stroke | 177 (13) | 292 (15) | 0.134 | |||
| Coronary artery disease | 103 (8) | 130 (7) | 0.284 | |||
| Other heart disease | 191 (15) | 270 (14) | 0.796 | |||
| Atrial fibrillation | 271 (21) | 353 (19) | 0.151 | |||
| Diabetes mellitus | 261 (20) | 368 (19) | 0.728 | |||
| Hypercholesterolemia | 291 (22) | 255 (13) | <0.0001 | 0.55 (0.45–0.66) | ||
| Current smoker | 311 (24) | 447 (24) | 0.919 | |||
| Pre-stroke function on the mRS | ||||||
| No symptoms | 1059 (81) | 1561 (82) | 0.238 | |||
| No significant disability | 257 (20) | 340 (18) | ||||
| Medications | ||||||
| Antihypertensive agents | 635 (48) | 826 (43) | 0.007 | 0.82 (0.71–0.95) | ||
| Warfarin anticoagulation | 32 (2) | 46 (2) | 0.971 | |||
| Aspirin/other antiplatelet agent(s) | 344 (26) | 388 (24) | 0.0001 | 0.72 (0.61–0.85) | ||
| Glucose-lowering treatment | 164 (13) | 238 (13) | 0.989 | |||
| Statin/other lipid lowering | 337 (26) | 267 (14) | <0.0001 | 0.47 (0.40–0.57) | ||
| Brain imaging features | N = 1316 | N = 1903 | ||||
| Visible early ischemic changes | 369 (28) | 390 (21) | <0.0001 | 0.66 (0.56–0.78) | ||
| Visible cerebral infarction | 341 (26) | 387 (20) | 0.0002 | 0.73 (0.62–0.86) | ||
| Visible cerebral infarction with mass effect | 19 (1) | 28 (2) | 0.949 | |||
| CT/MRI angiogram shows proximal occlusion | 295/1290 (23) | 203/1888 (11) | <0.0001 | 0.41 (0.33–0.49) | 0.65 (0.52–0.82) | 0.0002 |
| Final diagnosis at time of hospital separation | N = 1300 | N = 1877 | ||||
| Non-stroke | 51 (4) | 34 (2) | <0.0001 | |||
| Large artery occlusion due to significant atheroma | 421 (32) | 833 (44) | 1.0 | |||
| Small vessel or perforating vessel lacunar disease | 261 (20) | 404 (22) | 0.78 (0.64–0.95) | |||
| Cardioembolism | 301 (23) | 331 (18) | 0.56 (0.46–0.68) | |||
| Dissection | 15 (1) | 10 (1) | 0.52 (0.43–0.64) | |||
| Other or uncertain etiology | 251 (19) | 265 (14) | ||||
| Off-hour admission† | 627 (48) | 1153 (61) | <0.0001 | 1.69 (1.47–1.95) | 1.27 (1.07–1.50) | 0.005 |
| No. of patients treated in the center | 57 (33–106) | 96 (27–156) | <0.0001 | 1.04 (1.03–1.05) | 0.96 (0.95–0.97) | <0.0001 |
| Time from onset to door, hour | 1.5 (1.0–2.3) | 1.2 (0.8–1.9) | <0.0001 | 0.63 (0.58–0.68) | 0.58 (0.53–0.65) | <0.0001 |
Data are n (%), mean (SD), or median (IQR)· P values based on Chi-square, T test, or Wilcoxon signed-rank test.
aOR denotes adjusted odds ratio, BP blood pressure, CI confidence interval, CT computerized tomography, GCS Glasgow coma scale, mRS modified Rankin scale, MRI magnetic resonance imaging, NIHSS National Institutes of Health Stroke Scale, OR odds ratio.
*For every 10-unit increase.
†night time, weekend, and public holidays.
Door-to-Needle time over time.
| Fourth of time from the start of each center (days) | Unadjusted analysis | P value for interaction | Adjusted analysis* | P value for interaction | Median (IQR) | ||
|---|---|---|---|---|---|---|---|
| Mean (95%CI) | P value for interaction | Mean (95%CI) | P value for interaction | ||||
|
| 71.8 (70.4–73.2) | 0.003 | 0.003 | 72 (48–108) | |||
| 0–534 | 77.9 (74.9–80.9) | 78.2 (75.5–81.1) | 78 (48–120) | ||||
| 535–839 | 69.3 (66.7–72.0) | 70.3 (67.8–72.9) | 72 (48–108) | ||||
| 840–1056 | 69.1 (66.5–71.8) | 70.0 (67.5–72.6) | 72 (48–102) | ||||
| 1057–1262 | 71.4 (68.7–74.2) | 73.0 (70.4–75.7) | 72 (48–108) | ||||
|
| 97.5 (95.0–100.1) | <0.001 | <0.001 | <0.0001 | <0.001 | 102 (78–138) | |
| 0–534 | 123.0 (116.8–129.5) | 115.1 (107.9–122.7) | 126 (102–168) | ||||
| 535–839 | 98.7 (93.7–103.9) | 101.6 (95.1–108.6) | 108 (78–138) | ||||
| 840–1056 | 84.8 (80.8–89.0) | 92.3 (86.5–98.5) | 90 (60–120) | ||||
| 1057–1262 | 90.2 (85.9–94.8) | 95.6 (89.5–102.1) | 96 (66–132) | ||||
|
| 57.1 (55.8–58.3) | 0.065 | 0.083 | 54 (42–78) | |||
| 0–534 | 56.8 (54.4–59.4) | 56.5 (54.0–59.1) | 54 (42–78) | ||||
| 535–839 | 54.6 (52.2–57.0) | 52.7 (50.4–55.2) | 54 (42–78) | ||||
| 840–1056 | 57.7 (55.1–60.4) | 56.7 (54.1–59.5) | 60 (42–78) | ||||
| 1057–1262 | 59.4 (56.8–62.1) | 58.5 (55.8–61.3) | 60 (42–78) | ||||
CI denotes confidence interval; IQR denotes InterQuartile Range.
*Adjusted for time from onset to hospital arrival, sex, baseline diastolic blood pressure, Off-hour admission (night time, weekend, and public holidays), No. of patients treated in the center, and CT or MRI angiogram showing proximal occlusion.
Figure 1Correlation between time from the activation of each center in the ENCHANTED trial and door-to-needle time for (A) all patients, (B) Chinese patients, and (C) non-Chinese patients.